These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11747721)

  • 1. Rapid identification of Bordetella pertussis pertactin gene variants using LightCycler real-time polymerase chain reaction combined with melting curve analysis and gel electrophoresis.
    Mäkinen J; Viljanen MK; Mertsola J; Arvilommi H; He Q
    Emerg Infect Dis; 2001; 7(6):952-8. PubMed ID: 11747721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.
    Kodama A; Kamachi K; Horiuchi Y; Konda T; Arakawa Y
    J Clin Microbiol; 2004 Dec; 42(12):5453-7. PubMed ID: 15583264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene Variants.
    Muyldermans G; Piérard D; Hoebrekx N; Advani R; Van Amersfoorth S; De Schutter I; Soetens O; Eeckhout L; Malfroot A; Lauwers S
    J Clin Microbiol; 2004 Apr; 42(4):1614-9. PubMed ID: 15071014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland.
    Mooi FR; He Q; van Oirschot H; Mertsola J
    Infect Immun; 1999 Jun; 67(6):3133-4. PubMed ID: 10338531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis.
    Mäkinen J; Mertsola J; Viljanen MK; Arvilommi H; He Q
    J Clin Microbiol; 2002 Jun; 40(6):2213-6. PubMed ID: 12037089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.
    Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA
    Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.
    Byrne S; Slack AT
    BMC Infect Dis; 2006 Mar; 6():53. PubMed ID: 16542440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.
    Pawloski LC; Queenan AM; Cassiday PK; Lynch AS; Harrison MJ; Shang W; Williams MM; Bowden KE; Burgos-Rivera B; Qin X; Messonnier N; Tondella ML
    Clin Vaccine Immunol; 2014 Feb; 21(2):119-25. PubMed ID: 24256623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children.
    Mastrantonio P; Spigaglia P; Oirschot HV; van der Heide HGJ; Heuvelman K; Stefanelli P; Mooi FR
    Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():2069-2075. PubMed ID: 10463173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing Bordetella pertussis in Children, Philadelphia 2007-2014.
    Vodzak J; Queenan AM; Souder E; Evangelista AT; Long SS
    Clin Infect Dis; 2017 Jan; 64(1):60-66. PubMed ID: 27624959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
    Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.
    Zeddeman A; van Gent M; Heuvelman CJ; van der Heide HG; Bart MJ; Advani A; Hallander HO; Wirsing von Konig CH; Riffelman M; Storsaeter J; Vestrheim DF; Dalby T; Krogfelt KA; Fry NK; Barkoff AM; Mertsola J; He Q; Mooi F
    Euro Surveill; 2014 Aug; 19(33):. PubMed ID: 25166348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic variability of Bordetella pertussis strains. Part I. Current knowledge].
    Gzyl A; Augustynowicz E; Gniadek G; Slusarczyk J
    Przegl Epidemiol; 2003; 57(1):181-92. PubMed ID: 12926327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.
    Weber C; Boursaux-Eude C; Coralie G; Caro V; Guiso N
    J Clin Microbiol; 2001 Dec; 39(12):4396-403. PubMed ID: 11724851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
    Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
    Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years.
    Tsang RS; Shuel M; Jamieson FB; Drews S; Hoang L; Horsman G; Lefebvre B; Desai S; St-Laurent M
    Int J Infect Dis; 2014 Nov; 28():65-9. PubMed ID: 25244999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines.
    Zomer A; Otsuka N; Hiramatsu Y; Kamachi K; Nishimura N; Ozaki T; Poolman J; Geurtsen J
    Microb Genom; 2018 May; 4(5):. PubMed ID: 29771235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999.
    Cassiday P; Sanden G; Heuvelman K; Mooi F; Bisgard KM; Popovic T
    J Infect Dis; 2000 Nov; 182(5):1402-8. PubMed ID: 11023463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli.
    Hijnen M; van Gageldonk PG; Berbers GA; van Woerkom T; Mooi FR
    Protein Expr Purif; 2005 May; 41(1):106-12. PubMed ID: 15802227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan.
    Otsuka N; Han HJ; Toyoizumi-Ajisaka H; Nakamura Y; Arakawa Y; Shibayama K; Kamachi K
    PLoS One; 2012; 7(2):e31985. PubMed ID: 22348138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.